Intervention
Danvatirsen
ClinicalTrials.gov intervention label
Clinical trials
4 shownNeoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung CancerNCT03794544 · 2019-03-08
COMPLETEDA Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLCNCT03819465 · 2018-12-27
ACTIVE_NOT_RECRUITINGPhase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing TherapyNCT03334617 · 2017-12-18
ACTIVE_NOT_RECRUITINGDanvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal CancerNCT02983578 · 2017-03-02
ACTIVE_NOT_RECRUITINGCommon conditions
Advanced Colorectal Carcinoma1Advanced Lung Non-Small Cell Carcinoma1Early-stage1Lung Non-Small Cell Carcinoma1Metastatic Non-Small Cell Lung Cancer (NSCLC)1Mismatch Repair Deficiency1Non-Small Cell Lung Cancer1NSCLC1Refractory Colorectal Carcinoma1Refractory Lung Carcinoma1Refractory Pancreatic Carcinoma1Resectable1Stage II Pancreatic Cancer AJCC v81Stage III Colorectal Cancer AJCC v81Stage III Lung Cancer AJCC v81Stage III Pancreatic Cancer AJCC v81Stage IIIA Colorectal Cancer AJCC v81Stage IIIA Lung Cancer AJCC v81Stage IIIB Colorectal Cancer AJCC v81Stage IIIB Lung Cancer AJCC v81Stage IIIC Colorectal Cancer AJCC v81Stage IIIC Lung Cancer AJCC v81Stage IV Colorectal Cancer AJCC v81Stage IV Lung Cancer AJCC v81Stage IV Pancreatic Cancer AJCC v81
Leading sponsors
Trial status mix
ACTIVE_NOT_RECRUITING3
COMPLETED1
Phase mix
PHASE23
PHASE11
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.